Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBT (2016 - 2025)

Cumberland Pharmaceuticals' EBT history spans 16 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, EBT rose 28.92% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$2.8 million, up 56.53%, while the annual FY2025 figure was -$2.8 million, 56.53% up from the prior year.
  • EBT for Q4 2025 was -$1.4 million at Cumberland Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • Across five years, EBT topped out at $1.3 million in Q1 2025 and bottomed at -$4.4 million in Q4 2021.
  • The 5-year median for EBT is -$1.4 million (2022), against an average of -$1.1 million.
  • The largest annual shift saw EBT tumbled 1155.12% in 2024 before it soared 166.31% in 2025.
  • A 5-year view of EBT shows it stood at -$4.4 million in 2021, then skyrocketed by 44.88% to -$2.4 million in 2022, then soared by 56.2% to -$1.1 million in 2023, then plummeted by 85.43% to -$2.0 million in 2024, then rose by 28.92% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's EBT are -$1.4 million (Q4 2025), -$1.9 million (Q3 2025), and -$729536.0 (Q2 2025).